Vireo Growth (VREOF) FCF Margin (2020 - 2026)
Vireo Growth (VREOF) posted FCF Margin of 1.04% for Q1 2026, down 87.69% sequentially from 8.41% in Q4 2025, and up 1940.0% YoY from 0.05% in Q1 2025.
Vireo Growth (VREOF) FCF Margin (2020 - 2026) Analysis & Trends
Vireo Growth has reported FCF Margin for 7 years, with the latest figure at 1.04% in Q1 2026.
- Quarterly FCF Margin rose 1940.0% year-over-year to 1.04% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 5.43% (up 1896.0% YoY) and the FY2025 annual result came in at 9.16%, up 1291.0% from the prior year.
- FCF Margin slipped to 1.04% in Q1 2026 per VREOF's latest filing, from 8.41% in the prior quarter.
- Over five years, FCF Margin peaked at 8.41% in Q4 2025 and troughed at 57.13% in Q1 2022.
- A 5-year average of 17.54% and a median of 17.59% in 2025 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2024: FCF Margin soared 10796 bps in 2022, then plunged 3580 bps in 2024.
- Over 5 years, FCF Margin stood at 35.4% in 2022, then soared by 67 bps to 11.55% in 2023, then plunged by 217 bps to 36.62% in 2024, then jumped by 123 bps to 8.41% in 2025, then sank by 88 bps to 1.04% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 1.04%, 8.41%, and 22.31% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.65 Bn | 42.68 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.09 Bn | 39.44 Bn | 2.15 Bn | 7.41% |
| 3 | Zoetis | 31.54 Bn | 29.86 Bn | 1.05 Bn | 21.80% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 14.87% |
| 5 | United Therapeutics | 22.11 Bn | 19.45 Bn | 683.80 Mn | 26.25% |
| 6 | Viatris | 18.77 Bn | 17.88 Bn | 1.46 Bn | 8.76% |
| 7 | Neurocrine Biosciences | 15.62 Bn | 15.23 Bn | 935.80 Mn | 13.41% |
| 8 | Elanco Animal Health | 12.07 Bn | 11.54 Bn | 798.00 Mn | 17.84% |
| 9 | Dr Reddys Laboratories | 10.09 Bn | 9.93 Bn | - | - |
| 10 | Vireo Growth | 492.35 Mn | 350.05 Mn | 95.30 Mn | -50.55% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.04% |
| Dec 31, 2025 | 8.41% |
| Sep 30, 2025 | -22.31% |
| Jun 30, 2025 | -17.59% |
| Mar 31, 2025 | -18.37% |
| Dec 31, 2024 | -36.62% |
| Sep 30, 2024 | -29.71% |
| Jun 30, 2024 | -12.74% |
| Mar 31, 2024 | -8.68% |
| Dec 31, 2023 | -11.55% |
| Sep 30, 2023 | 6.09% |
| Jun 30, 2023 | -3.20% |
| Mar 31, 2023 | -20.92% |
| Dec 31, 2022 | -35.40% |
| Sep 30, 2022 | -16.59% |
| Jun 30, 2022 | -22.91% |
| Mar 31, 2022 | -57.13% |
| Dec 31, 2021 | -82.04% |
| Sep 30, 2021 | -66.11% |
| Jun 30, 2021 | -130.86% |